{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:31:34Z","timestamp":1780576294400,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-023-05524-x","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T17:03:26Z","timestamp":1706547806000},"page":"2921-2925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treat-to-target vs fixed interval retreatment strategy with rituximab in rheumatoid arthritis: a retrospective cohort study"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7999-4711","authenticated-orcid":false,"given":"Lisa","family":"Schapink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-2209","authenticated-orcid":false,"given":"Nathan","family":"den Broeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-4079","authenticated-orcid":false,"given":"Alfons A.","family":"den Broeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9740-5607","authenticated-orcid":false,"given":"Lise M.","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"5524_CR1","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann RDANCER, Group Study, et al. et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54:1390\u20131400. https:\/\/doi.org\/10.1002\/art.21778","journal-title":"Arthritis Rheum."},{"key":"5524_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40744-015-0016-9","volume":"2","author":"MD Cohen","year":"2015","unstructured":"Cohen MD, Keystone E (2015) Rituximab for Rheumatoid Arthritis. Rheumatol Ther 2:99\u2013111. https:\/\/doi.org\/10.1007\/s40744-015-0016-9","journal-title":"Rheumatol Ther"},{"issue":"350","key":"5524_CR3","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"04","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L et al (2004) Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 04(350):2572\u20132581. https:\/\/doi.org\/10.1056\/NEJMoa032534","journal-title":"N Engl J Med."},{"issue":"1","key":"5524_CR4","doi-asserted-by":"publisher","first-page":"e002898","DOI":"10.1136\/rmdopen-2022-002898","volume":"9","author":"CJT van der Togt","year":"2023","unstructured":"van der Togt CJT, Van den Bemt B et al (2023) Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD Open 9(1):e002898. https:\/\/doi.org\/10.1136\/rmdopen-2022-002898","journal-title":"RMD Open"},{"issue":"11","key":"5524_CR5","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1007\/s10067-019-04699-8","volume":"38","author":"S Tavakolpour","year":"2019","unstructured":"Tavakolpour S, Alesaeidi S et al (2019) A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol 38(11):2977\u20132994. https:\/\/doi.org\/10.1007\/s10067-019-04699-8","journal-title":"Clin Rheumatol"},{"key":"5524_CR6","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/rheumatology\/ker253","volume":"50","author":"P Emery","year":"2011","unstructured":"Emery P, Mease PJ et al (2011) Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxford) 50:2223\u201332. https:\/\/doi.org\/10.1093\/rheumatology\/ker253","journal-title":"Rheumatology (Oxford)"},{"key":"5524_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3899\/jrheum.160460","volume":"44","author":"K Chatzidionysiou","year":"2017","unstructured":"Chatzidionysiou K, Lie E et al (2017) Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. J Rheumatol. 44:162\u2013169. https:\/\/doi.org\/10.3899\/jrheum.160460","journal-title":"J Rheumatol."},{"key":"5524_CR8","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1136\/annrheumdis-2012-202281","volume":"72","author":"A Van der Maas","year":"2013","unstructured":"Van der Maas A, Lie E et al (2013) Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Ann Rheum Dis 72:1800\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202281","journal-title":"Ann Rheum Dis"},{"key":"5524_CR9","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1136\/annrheumdis-2013-203684","volume":"73","author":"JE Pope","year":"2014","unstructured":"Pope JE, Haraoui B et al (2014) The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis. 73:2144\u20132151. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203684","journal-title":"Ann Rheum Dis."},{"key":"5524_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(16)00380-9","volume":"388","author":"D Porter","year":"2016","unstructured":"Porter D, van Melckebeke MJ et al (2016) Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 388:239\u2013247. https:\/\/doi.org\/10.1016\/S0140-6736(16)00380-9","journal-title":"Lancet"},{"key":"5524_CR11","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s10067-015-2977-z","volume":"34","author":"M Bredemeier","year":"2015","unstructured":"Bredemeier M, Campos G, de Oliveira K et al (2015) Updates systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis. Clin Rheumatol. 34:1801\u20131805. https:\/\/doi.org\/10.1007\/s10067-015-2977-z","journal-title":"Clin Rheumatol."},{"key":"5524_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05524-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-023-05524-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05524-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T16:04:21Z","timestamp":1733328261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-023-05524-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":12,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5524"],"URL":"https:\/\/doi.org\/10.1007\/s00296-023-05524-x","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"assertion":[{"value":"19 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alfons A den Broeder received research grants to the institution from Abbvie, Pfizer, Lilly, Gilead, Novartis, Galapagos and Cellgene. Lisa Schapink, Nathan den Broeder, and Lise M Verhoef declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}